Trial reportFrontiers in cardiovascular medicine2026
Risk factors of bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention: an analysis from the MANJUSRI study.
Trial report in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The risk factors of bleeding related to dual or triple therapy in patients with atrial fibrillation after percutaneous coronary intervention (PCI) are not fully explored. We addressed this issue on patients enrolled in the MANJUSRI trial. Methods: Data of patients assigned to the dual therapy group (ticagrelor + warfarin, Dual group) and the triple group (clopidogrel + aspirin + warfarin, Triple group) in the MANJUSRI trial were analyzed. Multivariate regression analysis was used to determine the risk factors of bleeding among enrolled patients. Results: The incidence of overall bleeding at 6 months was 36.49% in the dual group and 35.62% in the triple group ( Conclusions: Alcohol consumption increased the risk of overall bleeding after PCI in atrial fibrillation patients, especially in patients treated with warfarin and ticagrelor. Aging also increased bleeding risk in the whole cohort. Lower body weight contributed significantly to increased risk of overall bleeding in AF patients post PCI receiving combined clopidogrel, aspirin and warfarin medications. Above factors should be considered in terms of individualized anticoagulation management in AF patients post PCI aiming to reduce their bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.